Heatwurx (NASDAQ:PCSA) Posts Earnings Results, Beats Expectations By $0.01 EPS

Heatwurx (NASDAQ:PCSA) released its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01, FiscalAI reports.

Heatwurx Price Performance

PCSA traded down $0.01 on Friday, hitting $0.31. The company had a trading volume of 2,096,921 shares, compared to its average volume of 9,369,590. The company’s fifty day moving average price is $0.27 and its 200 day moving average price is $0.25. Heatwurx has a 1-year low of $0.15 and a 1-year high of $1.50. The stock has a market cap of $15.40 million, a price-to-earnings ratio of -0.13 and a beta of 1.45.

Analysts Set New Price Targets

A number of brokerages have recently commented on PCSA. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heatwurx in a research report on Wednesday, October 8th. Zacks Research lowered Heatwurx from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. Finally, HC Wainwright cut their price objective on Heatwurx from $2.00 to $1.00 and set a “buy” rating on the stock in a report on Tuesday, September 2nd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Heatwurx has a consensus rating of “Hold” and an average target price of $1.00.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.